Arnab Chakravarti

13.2k total citations · 1 hit paper
123 papers, 5.7k citations indexed

About

Arnab Chakravarti is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arnab Chakravarti has authored 123 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Genetics, 34 papers in Oncology and 33 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arnab Chakravarti's work include Glioma Diagnosis and Treatment (67 papers), Radiomics and Machine Learning in Medical Imaging (20 papers) and Brain Metastases and Treatment (18 papers). Arnab Chakravarti is often cited by papers focused on Glioma Diagnosis and Treatment (67 papers), Radiomics and Machine Learning in Medical Imaging (20 papers) and Brain Metastases and Treatment (18 papers). Arnab Chakravarti collaborates with scholars based in United States, Canada and Israel. Arnab Chakravarti's co-authors include Minesh P. Mehta, Mark R. Gilbert, Roger Stupp, Jay S. Loeffler, Monika E. Hegi, Nicholas J. Dyson, Walter J. Curran, Daniel E. Weeks, Kenneth Aldape and Deborah T. Blumenthal and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Arnab Chakravarti

120 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

2013 742 citations Mark R. Gilbert, Meihua Wang et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arnab Chakravarti United States	36	2.8k	2.2k	1.5k	1.4k	1.3k	123	5.7k
Yannick Marie France	34	3.1k 1.1×	1.8k 0.9×	890 0.6×	567 0.4×	1.6k 1.2×	83	4.5k
V. Peter Collins Sweden	40	3.2k 1.1×	3.9k 1.8×	1.1k 0.8×	2.4k 1.7×	2.1k 1.6×	77	7.7k
Daniel P. Cahill United States	44	4.2k 1.5×	4.3k 2.0×	1.5k 1.0×	2.5k 1.8×	2.5k 1.8×	176	9.7k
Annelies de Klein Netherlands	52	2.5k 0.9×	5.2k 2.4×	1.4k 1.0×	1.9k 1.3×	786 0.6×	219	11.5k
C. Ryan Miller United States	44	1.4k 0.5×	3.4k 1.6×	1.3k 0.8×	2.0k 1.5×	1.2k 0.9×	156	6.3k
Ulrich Schüller Germany	37	1.5k 0.5×	2.5k 1.2×	400 0.3×	629 0.4×	661 0.5×	174	4.5k
Yueling Hao United States	11	2.0k 0.7×	3.5k 1.6×	496 0.3×	3.1k 2.2×	1.9k 1.4×	16	6.5k
Albert J. Wong United States	54	1.9k 0.7×	6.3k 2.9×	1.4k 0.9×	3.8k 2.7×	1.3k 1.0×	94	10.5k
Liliana Soroceanu United States	31	1.7k 0.6×	3.0k 1.4×	429 0.3×	1.3k 1.0×	1.5k 1.1×	46	6.0k
Paul A. Northcott United States	45	4.1k 1.5×	6.4k 3.0×	676 0.5×	1.1k 0.8×	2.0k 1.5×	120	8.6k

Countries citing papers authored by Arnab Chakravarti

Since Specialization

Citations

This map shows the geographic impact of Arnab Chakravarti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnab Chakravarti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnab Chakravarti more than expected).

Fields of papers citing papers by Arnab Chakravarti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnab Chakravarti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnab Chakravarti. The network helps show where Arnab Chakravarti may publish in the future.

Co-authorship network of co-authors of Arnab Chakravarti

This figure shows the co-authorship network connecting the top 25 collaborators of Arnab Chakravarti. A scholar is included among the top collaborators of Arnab Chakravarti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnab Chakravarti. Arnab Chakravarti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kumar, Anup, Sasha Beyer, Aline Paixão Becker, et al.. (2023). Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3β Pathway in Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 117(2). e121–e121. 1 indexed citations

Machtay, Mitchell, Pedro A. Torres‐Saavedra, Wade L. Thorstad, et al.. (2023). Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920. International Journal of Radiation Oncology*Biology*Physics. 117(4). e1–e1. 4 indexed citations

McClelland, Shearwood, et al.. (2021). Low-dose whole thorax radiation therapy for COVID-19 pneumonia: inpatient onboarding process for a randomized controlled trial. Reports of Practical Oncology & Radiotherapy. 26(6). 1057–1059. 2 indexed citations

Sherman, Eric J., Jonathan Harris, Keith C. Bible, et al.. (2020). 1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912. Annals of Oncology. 31. S1085–S1085. 4 indexed citations

Cui, Tiantian, Erica H. Bell, Joseph McElroy, et al.. (2020). A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma. Molecular Cancer Research. 19(1). 48–60. 17 indexed citations

Chakravarti, Arnab, et al.. (2020). Correlation of 25-hydroxy vitamin D3 levels with dengue disease severity–Can vitamin D levels predict dengue prognosis?. International Journal of Infectious Diseases. 101. 260–260. 1 indexed citations

Liu, Lu, Shurui Cai, Chunhua Han, et al.. (2019). ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2−/− Ovarian Cancer Cells. Molecular Cancer Therapeutics. 19(1). 199–210. 51 indexed citations

King, Paul D., Xiaohui Li, Charles D. Anderson, et al.. (2019). Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells. Journal of Neuro-Oncology. 143(2). 231–240. 9 indexed citations

Sizemore, Steven T., Gina M. Sizemore, Somaira Nowsheen, et al.. (2018). Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Molecular Cancer Research. 16(7). 1092–1102. 34 indexed citations

10.

Gittleman, Haley, Michael W. Kattan, Arnab Chakravarti, et al.. (2016). An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. Journal of Clinical Oncology. 34(15_suppl). 2007–2007. 29 indexed citations

11.

Gittleman, Haley, Michael W. Kattan, Arnab Chakravarti, et al.. (2016). An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Neuro-Oncology. 19(5). now208–now208. 131 indexed citations

12.

Gilbert, Mark R., Meihua Wang, Kenneth Aldape, et al.. (2013). Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology. 31(32). 4085–4091. 742 indexed citations breakdown →

13.

Meng, Wei, Zhenqing Ye, Ri Cui, et al.. (2013). MicroRNA-31 Predicts the Presence of Lymph Node Metastases and Survival in Patients with Lung Adenocarcinoma. Clinical Cancer Research. 19(19). 5423–5433. 93 indexed citations

14.

Sanchez, Carlos E., Diahnn Futalan, David Gonda, et al.. (2012). CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy. Journal of Neuro-Oncology. 110(1). 37–48. 7 indexed citations

15.

Russo, Andrea, Hyuk‐Chan Kwon, William Burgan, et al.. (2009). In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016. Clinical Cancer Research. 15(2). 607–612. 132 indexed citations

16.

El‐Jawahri, Areej, Disha Patel, Min Zhang, Nikol Mladkova, & Arnab Chakravarti. (2008). Biomarkers of Clinical Responsiveness in Brain Tumor Patients. Molecular Diagnosis & Therapy. 12(4). 199–208. 9 indexed citations

17.

Stupp, Roger, Monika E. Hegi, Mark R. Gilbert, & Arnab Chakravarti. (2007). Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions. Journal of Clinical Oncology. 25(26). 4127–4136. 396 indexed citations

18.

Siker, Malika, Arnab Chakravarti, & Minesh P. Mehta. (2006). Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?. Critical Reviews in Oncology/Hematology. 60(2). 99–111. 28 indexed citations

19.

Chowdari, Kodavali V., et al.. (2000). TDT: Advantages & disadvantages for mapping studies of schizophrenia. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 96(4). 1 indexed citations

20.

Chakravarti, Arnab, et al.. (1999). Bell’s Palsy — herpes simplex virus type-1 a possible causative agent. Indian Journal of Otolaryngology and Head & Neck Surgery. 51(2). 47–50. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact